Efficacy of exercise in reducing depressive symptoms across 5-HTTLPR genotypes.

INTRODUCTION Exercise is effective in the alleviation of depressive symptoms and may have physiological effects similar to those of selective serotonin reuptake inhibitors (SSRI). Recent research has identified the difference in treatment effects across genetic polymorphisms of the serotonin transporter polymorphic region (5-HTTLPR), in which the l allele has been associated with a better response to SSRI compared with the s allele. The purpose of the current research was to examine the antidepressant effects of exercise across 5-HTTLPR genotypes. METHODS Participants, ages 18–23 yr, were randomly assigned to a 5-wk exercise intervention or a no-treatment control group. Participants completed the Beck Depression Inventory before and after the intervention and provided a saliva sample for DNA analysis. RESULTS Exercise resulted in a significant reduction in depressive symptoms compared with the control group. In addition, individuals with at least one l allele demonstrated greater reductions in depressive symptoms compared with ss individuals. CONCLUSIONS The effects of exercise on depressive symptoms appear to be moderated by 5-HTTLPR genotype, suggesting that the mechanisms responsible for the alleviation of depressive symptoms are similar for exercise and SSRI treatment. Furthermore, these findings suggest that 5-HTTLPR genotype should be a factor in determining the proper line of treatment for depression.

[1]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[2]  M. Fleshner,et al.  Wheel running alters serotonin (5-HT) transporter, 5-HT1A, 5-HT1B, and alpha1b-adrenergic receptor mRNA in the rat raphe nuclei , 2005, Biological Psychiatry.

[3]  D. Murphy,et al.  Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. , 1993, Brain research. Molecular brain research.

[4]  The effect of exercise on depressive symptoms in the moderately depressed elderly. , 1991, Psychology and aging.

[5]  Debbie A Lawlor,et al.  The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials , 2001, BMJ : British Medical Journal.

[6]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[7]  D. Landers,et al.  An examination of serotonin and psychological variables in the relationship between exercise and mental health , 2011, Scandinavian journal of medicine & science in sports.

[8]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[9]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[10]  P. Pilkonis,et al.  Treatment expectancies, patient alliance, and outcome: further analyses from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. , 2002, Journal of consulting and clinical psychology.

[11]  F. Petty,et al.  Whole-blood serotonin in children and adolescents with mood and behavior disorders , 1996, Psychiatry Research.

[12]  K. Goa,et al.  Citalopram , 2012, Drugs.

[13]  A. Najlerahim,et al.  Expression of serotonin transporter mRNA in rat brain: Presence in neuronal and non-neuronal cells and effect of paroxetine , 1997, Journal of Chemical Neuroanatomy.

[14]  K. Lesch,et al.  Serotonergic gene expression and depression: implications for developing novel antidepressants. , 2001, Journal of affective disorders.

[15]  A. Serretti,et al.  Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients , 2007, Molecular Psychiatry.

[16]  Y. Conwell,et al.  The clinical significance of subsyndromal depression in older primary care patients. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[17]  Mark B. Powers,et al.  Exercise interventions for mental health: A quantitative and qualitative review , 2006 .

[18]  Sean P David,et al.  A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT1A Receptor Binding in Humans , 2005, The Journal of Neuroscience.

[19]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[20]  G. Zimet,et al.  The Multidimensional Scale of Perceived Social Support , 1988 .

[21]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[22]  James H. Johnson,et al.  Assessing the impact of life changes: development of the Life Experiences Survey. , 1978, Journal of consulting and clinical psychology.

[23]  E. Smeraldi,et al.  Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. , 2000, Journal of clinical psychopharmacology.

[24]  S. Clissold,et al.  Paroxetine , 1991, Drugs.

[25]  M. Jakovljevič,et al.  Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. , 1991, Journal of affective disorders.

[26]  K. Wells,et al.  Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. , 1996, The American journal of psychiatry.

[27]  D. Landers,et al.  The Antidepressive Effects of Exercise , 2009, Sports medicine.

[28]  Claudette Boni,et al.  Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine , 2000, Neuropharmacology.

[29]  P. Goodnick,et al.  Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression , 2000, Biological Psychiatry.

[30]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[31]  S D Imber,et al.  National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. , 1989, Archives of general psychiatry.

[32]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[33]  D. Landers,et al.  The Effect of Exercise on Clinical Depression and Depression Resulting from Mental Illness: A Meta-Analysis , 1998 .

[34]  L. George,et al.  Depression, disability days, and days lost from work in a prospective epidemiologic survey. , 1990, JAMA.

[35]  Jack M. Gorman,et al.  A Guide to Treatments That Work , 2007 .

[36]  J. González-Olvera,et al.  TRYPTOPHAN AND SEROTONIN IN BLOOD AND PLATELETS OF DEPRESSED PATIENTS: EFFECT OF AN ANTIDEPRESSANT TREATMENT , 2006 .

[37]  M. Fiatarone,et al.  A randomized controlled trial of progressive resistance training in depressed elders. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

[38]  P. Platen,et al.  Effect of acute and chronic exercise on plasma amino acids and prolactin concentrations and on [3H]ketanserin binding to serotonin2A receptors on human platelets , 1999, European Journal of Applied Physiology and Occupational Physiology.

[39]  Henry Kranzler,et al.  Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects , 1997, Human Genetics.

[40]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[41]  L. Judd,et al.  Subsyndromal symptomatic depression: a new mood disorder? , 1994, The Journal of clinical psychiatry.

[42]  P. Shrout,et al.  Minor depression in a cohort of young adults in Israel. , 1994, Archives of general psychiatry.

[43]  B. Jacobs.  Serotonin, Motor Activity and Depression-Related Disorders , 1994 .

[44]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[45]  K. Gadde,et al.  Central Nervous System Serotonin Function and Cardiovascular Responses to Stress , 2001, Psychosomatic medicine.

[46]  C. Nemeroff,et al.  Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.

[47]  J. Neumaier,et al.  Chronic Fluoxetine Reduces Serotonin Transporter mRNA and 5-HT1B mRNA in a Sequential Manner in the Rat Dorsal Raphe Nucleus , 1996, Neuropsychopharmacology.

[48]  Z. Tran,et al.  Effect of Exercise on Depression , 1990, Exercise and sport sciences reviews.

[49]  J. Gaillard,et al.  Platelet Serotonin and Plasma Tryptophan in Depressed Patients: Effect of Drug Treatment and Clinical Outcome , 1994, Neuropsychopharmacology.

[50]  Influence of aerobic exercise on depression. , 1984, Journal of personality and social psychology.

[51]  G. Andrews,et al.  Using epidemiological data to model efficiency in reducing the burden of depression* , 2000, The journal of mental health policy and economics.

[52]  J. Neumaier,et al.  Antidepressant‐induced regulation of 5‐HT1b mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation , 2000, Journal of neuroscience research.